2. Academic Validation
  3. Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397)

Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3- hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397)

  • J Med Chem. 1999 Dec 16;42(25):5061-3. doi: 10.1021/jm990517p.
H Kawamoto 1,  S Ozaki,  Y Itoh,  M Miyaji,  S Arai,  H Nakashima,  T Kato,  H Ohta,  Y Iwasawa
Affiliations

Affiliation

  • 1 Banyu Tsukuba Research Institute in collaboration with Merck Research Laboratories, Banyu Pharmaceutical Company Ltd., Okubo 3, Tsukuba, Ibaraki 300-2611, Japan.
PMID: 10602690 DOI: 10.1021/jm990517p
Figures